125 related articles for article (PubMed ID: 17127618)
1. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.
Alving CR; Beck Z; Karasavva N; Matyas GR; Rao M
Mol Membr Biol; 2006; 23(6):453-65. PubMed ID: 17127618
[TBL] [Abstract][Full Text] [Related]
2. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
Huarte N; Lorizate M; Kunert R; Nieva JL
FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
[TBL] [Abstract][Full Text] [Related]
3. Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.
Beck Z; Karasavvas N; Matyas GR; Alving CR
J Drug Target; 2008 Aug; 16(7):535-42. PubMed ID: 18686123
[TBL] [Abstract][Full Text] [Related]
4. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.
Sánchez-Martínez S; Lorizate M; Hermann K; Kunert R; Basañez G; Nieva JL
FEBS Lett; 2006 Apr; 580(9):2395-99. PubMed ID: 16616522
[TBL] [Abstract][Full Text] [Related]
5. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
6. Sphingolipids: modulators of HIV-1 infection and pathogenesis.
Rawat SS; Johnson BT; Puri A
Biosci Rep; 2005; 25(5-6):329-43. PubMed ID: 16307380
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
[TBL] [Abstract][Full Text] [Related]
8. Antibodies against heat shock proteins and cholesterol in HIV infection.
Füst G; Beck Z; Bánhegyi D; Kocsis J; Bíró A; Prohászka Z
Mol Immunol; 2005 Jan; 42(1):79-85. PubMed ID: 15488946
[TBL] [Abstract][Full Text] [Related]
9. Lipid A and liposomes containing lipid A as antigens and adjuvants.
Alving CR; Rao M
Vaccine; 2008 Jun; 26(24):3036-45. PubMed ID: 18226433
[TBL] [Abstract][Full Text] [Related]
10. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
11. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
[TBL] [Abstract][Full Text] [Related]
12. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
13. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
14. Dynamic tradeoffs in the raft-mediated entry of human immunodeficiency virus type 1 into cells.
Lim KI; Yin J
Biotechnol Bioeng; 2006 Feb; 93(2):246-57. PubMed ID: 16136590
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.
Raulin J
Prog Lipid Res; 2002 Jan; 41(1):27-65. PubMed ID: 11694268
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to liposomes, phospholipids, and cholesterol: implications for autoimmunity, atherosclerosis, and aging.
Alving CR
Prog Clin Biol Res; 1990; 343():41-51. PubMed ID: 2198584
[No Abstract] [Full Text] [Related]
17. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review).
Rawat SS; Viard M; Gallo SA; Rein A; Blumenthal R; Puri A
Mol Membr Biol; 2003; 20(3):243-54. PubMed ID: 12893532
[TBL] [Abstract][Full Text] [Related]
18. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Haynes BF; Montefiori DC
Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5.
Kusov YY; Zamjatina NA; Poleschuk VF; Michailov MI; Morace G; Eberle J; Gauss-Müller V
Antiviral Res; 2007 Feb; 73(2):101-11. PubMed ID: 17014915
[TBL] [Abstract][Full Text] [Related]
20. Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes.
Karasavvas N; Beck Z; Tong J; Matyas GR; Rao M; McCutchan FE; Michael NL; Alving CR
Biochem Biophys Res Commun; 2008 Feb; 366(4):982-7. PubMed ID: 18088597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
